Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of Simmitinib in Advanced Solid Tumors
NCT04058587Phase 1Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Jun 2020
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Cimetinib in solid tumor (advanced stage), gastric cancer (GC), cholangiocarcinoma (CCA) and 3 more, sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose-Limiting Toxicity at 1 year, Maximum Tolerated Dose at 1 year and 1 more. Status: unknown.
02
Drugs
Cimetinib
03
Conditions
solid tumor (advanced stage)gastric cancer (GC)cholangiocarcinoma (CCA)squamous cell carcinoma of the lung (LSCC)urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT04058587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04058587.